EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Computed Tomography‐Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non‐Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and Immunotherapy

Yuxin Geng, Tianwen Yin, Yikun Li, Kaixing He, Bingwen Zou, Jinming Yu iD, Xiao Sun, Tao Zhang, Feifei Teng iD

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Yuxin Geng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Genomics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The work was backed up by grants from the Academic Promotion Program of Shandong First Medical University (Grant 2019ZL002), and the National Natural Science F….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The standard therapy for locally unresectable advanced non‐small cell lung cancer (NSCLC) is comprised of chemoradiotherapy (CRT) before immunotherapy (IO) consolidation. However, how to predict treatment outcomes and recognize patients that will benefit from IO remain unclear. This study aimed to identify prognostic biomarkers by integrating computed tomography (CT)‐based radiomics and genomics. Specifically, our research involved 165 patients suffering from unresectable Stage III NSCLC. Cohort 1 (IO following CRT) was divided into D1 ( n = 74), D2 ( n = 32), and D3 ( n = 26) sets, and the remaining 33 patients treated with CRT alone were grouped in D4. According to the CT images of primary tumor regions, radiomic features were analyzed through the least absolute shrinkage and selection operator (LASSO) regression. The Rad‐score was figured out to forecast the progression‐free survival (PFS). According to the Rad‐score, patients were divided into high and low risk groups. Next‐generation sequencing was implemented on peripheral blood and tumor tissue samples in the D3 and D4 cohorts. The maximum somatic allele frequency (MSAF) about circulating tumor DNA levels was assessed. Mismatch repair and switching/sucrose non‐fermenting signaling pathways were significantly enriched in the low‐risk group compared to the high‐risk group ( p < 0.05). Moreover, patients with MSAF ≥ 1% and those showing a decrease in MSAF after treatment significantly benefited from IO. This study developed a radiomics model predicting PFS after CRT and IO in Stage III NSCLC and constructed a radio‐genomic map to identify underlying biomarkers, supplying valuable insights for cancer biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyGenomicsImmunotherapyTomography, X-Ray ComputedHumansFemaleMaleMiddle AgedAgedPrognosisNeoplasm StagingBiomarkers, TumorAdultRadiomics

Stichwörter der Autor:innen

chemoradiotherapygenomicsimmunotherapynon‐small cell lung cancerradiomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China.
  • Department of Breast Surgery, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
  • Department of Radiation Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Jinming Yu, Feifei Teng

Förderung

  • The work was backed up by grants from the Academic Promotion Program of Shandong First Medical University (Grant 2019ZL002), and the National Natural Science F…

Zitieren

APA

Geng, Y., Yin, T., Li, Y., He, K., Zou, B., Yu, J., Sun, X., Zhang, T., & Teng, F. (2025). Computed Tomography‐Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non‐Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and Immunotherapy. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23883

Vancouver

Geng Y, Yin T, Li Y, He K, Zou B, Yu J, et al. Computed Tomography‐Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non‐Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and Immunotherapy. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23883

BibTeX
@article{Geng2025,
  author = {Geng, Yuxin and Yin, Tianwen and Li, Yikun and He, Kaixing and Zou, Bingwen and Yu, Jinming and Sun, Xiao and Zhang, Tao and Teng, Feifei},
  title = {Computed Tomography‐Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non‐Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and Immunotherapy},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23883}
}
Kostenlos starten →